RECORDATI |
Market Closed -
Other stock markets
|
After market 18:19:36 | |||
| 50.5 EUR | -0.59% |
|
50.45 | -0.10% |
| 05-10 | Futures bullish; Mib restarts at 34,300 level | AN |
| 05-09 | Mib up, Nexi and Prysmian good after accounts | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
19/05/2024
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
50.8
EUR
Average target price
52.24
EUR
Spread / Average Target
+2.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.42% | 11.29B | |
| +29.53% | 684B | |
| +30.34% | 568B | |
| -3.96% | 361B | |
| +17.67% | 329B | |
| +4.01% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| +6.96% | 166B |
- Stock Market
- Equities
- REC Stock
- News Recordati
- Recordati to Pursue Further Talks with US FDA on Development of Neuroblastoma Treatment
